Sino Medical Sciences Technology Inc.
14
2
4
7
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 60/100
14.3%
2 terminated/withdrawn out of 14 trials
77.8%
-8.7% vs industry average
7%
1 trials in Phase 3/4
29%
2 of 7 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (14)
Compare the Effectiveness and Safety of Two Different Kinds of Cutting Balloon in Coronary Artery Disease
Role: lead
PIONEER III Trial to Assess Safety and Efficacy of the BuMA Supreme™ Drug Coated Coronary Stent in Patients With Coronary Disease
Role: lead
Comparison Three vs Six Months of Dual Anti-platelet Therapy After Sirolimus-eluting Stent Implantation
Role: lead
Dual Anti-Platelet Optimized Stent for High Bleeding Risk Patient
Role: collaborator
A Registry Study of Intracranial Atherosclerotic Stenosis Treatment by Intracranial Drug-eluting Stenting in China
Role: lead
Standardized Procedure for Intracranial Drug-Eluting Stenting in the Treatment of Intracranial Atherosclerotic Stenosis
Role: lead
A Study to Evaluate the Impact of 11-month Ticagrelor Monotherapy Following One-month DAPT After PCI
Role: lead
A Study to Evaluate the Efficacy and Safety of BuMA Supreme Drug Eluting Stent(DES)
Role: lead
A Study to Evaluate the Efficacy and Safety of BuMA Supreme Drug Eluting Stent(DES)
Role: lead
First-in-man Trial Evaluating the Safety and Efficacy of the NOVA Intracranial Stent (NOVA Trial)
Role: lead
A Comparative Evaluation of the Extent of Neointima Formation at 1 Month and 2 Months After Implantation Using OCT
Role: lead
First-in-man Trial Examining the Safety and Efficacy of BuMA Supreme and Resolute Integrity in Patients With de Novo Coronary Artery Stenosis
Role: lead
Comparison of BuMA eG Based BioDegradable Polymer Stent With EXCEL Biodegradable Polymer Sirolimus-eluting Stent in "Real-World" Practice
Role: lead
BuMA OCT Study(A Comparative Evaluation of the Extent of Neointima Formation at 3 Months After Implantation Using OCT)
Role: lead
All 14 trials loaded